<--- Back to Details
First PageDocument Content
Health / Pharmaceuticals policy / Clinical research / Federal Department of Home Affairs / Swissmedic / Pharmaceutical industry / Healthcare quality / Marketing authorization / Statistical process control / Pharmacovigilance / IB / Bioequivalence
Health
Pharmaceuticals policy
Clinical research
Federal Department of Home Affairs
Swissmedic
Pharmaceutical industry
Healthcare quality
Marketing authorization
Statistical process control
Pharmacovigilance
IB
Bioequivalence

ZL300_00_001e_WL Guidance document Variations and extensions HMV4

Add to Reading List

Source URL: www.swissmedic.ch

Download Document from Source Website

File Size: 434,97 KB

Share Document on Facebook

Similar Documents

House of Commons Health Committee The Influence of the Pharmaceutical Industry

DocID: 1v3YA - View Document

Speakers Confirmed BD Biosciences Industry Days A roadshow of talks specifically tailored to those working in the biotechnology, clinical research and pharmaceutical industry. Join leaders in the field and BD experts for

DocID: 1uWLK - View Document

NEWS RELEASE Copley Scientific celebrates seven decades of responsive service to the pharmaceutical industry 17th May 2016: Nottingham, UK: Copley Scientific, a family-owned company that began supplying glassware to the

DocID: 1utWK - View Document

2nd APV Conference on “Highly Potent Drug Products in the Pharmaceutical Industry” 26 to 27 September 2018 Mannheim, Germany

DocID: 1utU5 - View Document

Index of abbreviations AAMC – Australian Army Medical Corps AB – Artium Baccalaureus, Bachelor of Arts Aberd – Aberdeen ABPI – Association of the British Pharmaceutical Industry AC – Companion, Order of Austral

DocID: 1ushC - View Document